MX375863B - Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) - Google Patents

Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)

Info

Publication number
MX375863B
MX375863B MX2017006563A MX2017006563A MX375863B MX 375863 B MX375863 B MX 375863B MX 2017006563 A MX2017006563 A MX 2017006563A MX 2017006563 A MX2017006563 A MX 2017006563A MX 375863 B MX375863 B MX 375863B
Authority
MX
Mexico
Prior art keywords
farnesoid
fxr
steroids
receptor
hydroxy
Prior art date
Application number
MX2017006563A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006563A (es
Inventor
Alexander Weymouth-Wilson
Carl Otter
James Boydell
Laura Wallis
Rhys Batchelor
Zofia Komsta
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1420594.2A external-priority patent/GB201420594D0/en
Priority claimed from GBGB1420593.4A external-priority patent/GB201420593D0/en
Priority claimed from GBGB1505670.8A external-priority patent/GB201505670D0/en
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Publication of MX2017006563A publication Critical patent/MX2017006563A/es
Publication of MX375863B publication Critical patent/MX375863B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017006563A 2014-11-19 2015-11-19 Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) MX375863B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1420594.2A GB201420594D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1420593.4A GB201420593D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1505670.8A GB201505670D0 (en) 2015-04-01 2015-04-01 Compounds
PCT/GB2015/053516 WO2016079517A1 (en) 2014-11-19 2015-11-19 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators

Publications (2)

Publication Number Publication Date
MX2017006563A MX2017006563A (es) 2018-01-26
MX375863B true MX375863B (es) 2025-03-07

Family

ID=54704019

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006563A MX375863B (es) 2014-11-19 2015-11-19 Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)

Country Status (15)

Country Link
US (1) US10301350B2 (enExample)
EP (1) EP3221331B1 (enExample)
JP (1) JP6700274B2 (enExample)
KR (1) KR102526631B1 (enExample)
CN (1) CN107207559B (enExample)
BR (1) BR112017010319B1 (enExample)
CA (1) CA2968309A1 (enExample)
DK (1) DK3221331T3 (enExample)
EA (1) EA033427B1 (enExample)
ES (1) ES2759725T3 (enExample)
MX (1) MX375863B (enExample)
PL (1) PL3221331T3 (enExample)
PT (1) PT3221331T (enExample)
TW (1) TWI690536B (enExample)
WO (1) WO2016079517A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI686400B (zh) 2014-11-19 2020-03-01 英商Ｎｚｐ英國有限公司 化合物（二）
EA033603B1 (ru) 2014-11-19 2019-11-08 Nzp Uk Ltd 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
CZ2015504A3 (cs) * 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
EA201891491A1 (ru) * 2015-12-22 2018-11-30 Интерсепт Фармасьютикалз, Инк. Полиморфные кристаллические формы обетихолевой кислоты
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
WO2018102418A1 (en) * 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
EP3431486A1 (en) 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
CN111138509B (zh) * 2018-11-02 2022-12-06 东莞东阳光药物研发有限公司 奥贝胆酸的制备方法
CN112521438B (zh) * 2020-12-08 2021-11-23 苏利制药科技江阴有限公司 一种β-谷甾醇的合成工艺
WO2023288123A1 (en) * 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
CN113912661B (zh) * 2021-11-11 2023-04-21 湖南科瑞生物制药股份有限公司 一种7-羟基甾体化合物的合成方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
WO1993021259A1 (en) 1992-04-14 1993-10-28 Cornell Research Foundation Inc. Dendritic based macromolecules and method of production
WO1994019366A1 (en) 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7138390B2 (en) 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
KR100948532B1 (ko) 2001-11-07 2010-03-23 넥타르 테라퓨틱스 분지형 중합체 및 그의 공액체
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) * 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
CN101395170A (zh) 2006-02-14 2009-03-25 英特塞普特药品公司 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
CA2928178C (en) 2007-01-19 2019-09-10 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
EA020310B1 (ru) 2008-07-30 2014-10-30 Интерсепт Фармасьютикалз, Инк. Модуляторы рецептора tgr5 и их применение
ES2592452T3 (es) * 2008-11-19 2016-11-30 Intercept Pharmaceuticals, Inc. Moduladores de TGR5 y métodos de uso de los mismos
AU2009316566B9 (en) 2008-11-19 2014-05-15 Intercept Pharmaceuticals, Inc. TGR5 modulators and method of use thereof
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
WO2014066819A1 (en) 2012-10-26 2014-05-01 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
KR102106186B1 (ko) 2012-11-28 2020-05-04 인터셉트 파마슈티컬즈, 인크. 폐 질환의 치료
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
HRP20180931T1 (hr) 2013-05-14 2018-10-05 Intercept Pharmaceuticals, Inc. 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x
RU2015155552A (ru) 2013-05-24 2017-06-27 Нестек С.А. Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
ES2938874T3 (es) 2014-05-29 2023-04-17 Bar Pharmaceuticals S R L Derivados de colano para su uso en el tratamiento y/o prevención de enfermedades mediadas por FXR y TGR5/GPBAR1
CA2966885A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
EA033603B1 (ru) 2014-11-19 2019-11-08 Nzp Uk Ltd 6-альфа-алкил-6,7-дионовые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
TWI686400B (zh) 2014-11-19 2020-03-01 英商Ｎｚｐ英國有限公司 化合物（二）
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
HK1244708A1 (zh) 2014-11-26 2018-08-17 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物及其使用方法
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
PL3310801T3 (pl) 2015-06-19 2021-11-22 Intercept Pharmaceuticals, Inc. Modulatory tgr5 i sposoby ich stosowania
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
PL3221331T3 (pl) 2020-03-31
ES2759725T3 (es) 2020-05-12
EA033427B1 (ru) 2019-10-31
EA201790884A8 (ru) 2019-07-31
DK3221331T3 (da) 2019-12-02
CN107207559A (zh) 2017-09-26
MX2017006563A (es) 2018-01-26
CA2968309A1 (en) 2016-05-26
HK1246801A1 (en) 2018-09-14
US10301350B2 (en) 2019-05-28
WO2016079517A1 (en) 2016-05-26
US20170327528A1 (en) 2017-11-16
EA201790884A1 (ru) 2017-11-30
TW201632537A (zh) 2016-09-16
KR102526631B1 (ko) 2023-04-27
BR112017010319A2 (pt) 2017-12-26
PT3221331T (pt) 2019-12-23
JP2017534670A (ja) 2017-11-24
EP3221331A1 (en) 2017-09-27
BR112017010319B1 (pt) 2023-04-11
CN107207559B (zh) 2019-10-25
EP3221331B1 (en) 2019-09-18
NZ731924A (en) 2020-12-18
JP6700274B2 (ja) 2020-05-27
TWI690536B (zh) 2020-04-11
KR20170086604A (ko) 2017-07-26

Similar Documents

Publication Publication Date Title
MX375863B (es) Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
MX375865B (es) Esteroides de 6.alfa-alquil-3,7-diona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr).
MX375864B (es) Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
MX381239B (es) Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
JOP20190022B1 (ar) ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
MX2020004024A (es) Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1.
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
EA201992183A2 (ru) Синтез полициклических карбамоилпиридоновых соединений
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CO2017001884A2 (es) Polimorfos de selinexor
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MX2015013792A (es) Sonda fluorescente estañosa.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
MX389099B (es) Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos.
UY34819A (es) Derivados de ß-aminoácido sustituidos como antagonistas del receptor CXCR3.
CO7051029A2 (es) Proceso para la preparacion de fenilpropanonas sustituidas

Legal Events

Date Code Title Description
FG Grant or registration